Skip to main content
Erschienen in: Pituitary 6/2016

06.09.2016

Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels

verfasst von: Alina Livshits, Jelena Kravarusic, Ellie Chuang, Mark E. Molitch

Erschienen in: Pituitary | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this case report is to demonstrate that the simple expedient of measuring periodic prolactin levels in patients with MEN1 who have modest hyperprolactinemia and normal pituitary MRI scans is insufficient to monitor for the development of pituitary adenomas.

Methods

Review of relevant literature and chart review.

Results

A 25 year old man with known MEN1 manifested by hyperparathyroidism and a gastrin-producing neuroendocrine tumor was found to have a prolactin [PRL] level of 20.0 ng/mL [1.6–16 ng/mL] but a normal pituitary MRI scan. The impression then was that he had prolactinoma too small to be visualized on the MRI. Over the next 3.5 years his PRL levels remained in this mildly elevated range but he then presented with severe headaches and visual field defects. An MRI showed a 3.1 × 1.7 × 1.9 cm pituitary adenoma with compression of the optic chiasm and invasion of the left cavernous sinus. Surgery revealed a gonadotroph adenoma and he subsequently required gamma knife radiotherapy for residual tumor. Postoperative PRL levels were normal.

Conclusions

Small, intrasellar microadenomas may be associated with elevated PRL levels due to possible direct hormone production [prolactinoma] or possibly to interference with portal vessel blood flow. In monitoring hyperprolactinemic MEN1 patients for the development of pituitary adenomas, measurement of PRL levels is insufficient and periodic MRI scans are necessary at a more frequent interval than every 3–5 years. This may also pertain to patients with “idiopathic” hyperprolactinemia.
Literatur
1.
Zurück zum Zitat Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370CrossRefPubMed Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370CrossRefPubMed
2.
Zurück zum Zitat Burgess J, Shepherd J, Parameswaran V, Hoffman L, Greenaway T (1996) Spectrum of pituitary disease in multiple endocrine neoplasia type 1 [MEN 1]: clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 81:2642–2646PubMed Burgess J, Shepherd J, Parameswaran V, Hoffman L, Greenaway T (1996) Spectrum of pituitary disease in multiple endocrine neoplasia type 1 [MEN 1]: clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 81:2642–2646PubMed
3.
Zurück zum Zitat O’Brien T, O’Riordan D, Gharib H, Scheithauer BW, Ebersold M, van Heerden JA (1996) Results of treatment of pituitary disease in multiple endocrine neoplasia, type 1. Neurosurgery 39:273–279CrossRefPubMed O’Brien T, O’Riordan D, Gharib H, Scheithauer BW, Ebersold M, van Heerden JA (1996) Results of treatment of pituitary disease in multiple endocrine neoplasia, type 1. Neurosurgery 39:273–279CrossRefPubMed
4.
Zurück zum Zitat Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A, Members of the Groupe d’Etude des Neopalsmies Endocriniennes Multiples (2002) Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465CrossRefPubMed Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A, Members of the Groupe d’Etude des Neopalsmies Endocriniennes Multiples (2002) Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465CrossRefPubMed
5.
Zurück zum Zitat Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Hobbs GR, Gibril F, Jensen RT, Marx SJ (2004) Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 89:3776–3784CrossRefPubMed Hao W, Skarulis MC, Simonds WF, Weinstein LS, Agarwal SK, Mateo C, James-Newton L, Hobbs GR, Gibril F, Jensen RT, Marx SJ (2004) Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 89:3776–3784CrossRefPubMed
6.
Zurück zum Zitat Vierimaa O, Ebeling TML, Kytölä S, Bloigu R, Eloranta E, Salmi J, Korpi-Hyöväti E, Niskanen L, Orvola A, Elovaara E, Gynther A, Sane T, Välimäki M, Ignatius J, Leisti J, Salmela PI (2007) Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype-phenotype correlation. Eur J Endocrinol 157:285–294CrossRefPubMed Vierimaa O, Ebeling TML, Kytölä S, Bloigu R, Eloranta E, Salmi J, Korpi-Hyöväti E, Niskanen L, Orvola A, Elovaara E, Gynther A, Sane T, Välimäki M, Ignatius J, Leisti J, Salmela PI (2007) Multiple endocrine neoplasia type 1 in Northern Finland; clinical features and genotype-phenotype correlation. Eur J Endocrinol 157:285–294CrossRefPubMed
7.
Zurück zum Zitat De Laat JM, Dekkers OM, Pieterman CRC, Kluifjhout WP, Hermus AR, Pereira AM, van den Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, de Herder WW, Valk GD (2015) Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group [DMSG]. J Clin Endocrinol Metab 100:3288–3296CrossRefPubMed De Laat JM, Dekkers OM, Pieterman CRC, Kluifjhout WP, Hermus AR, Pereira AM, van den Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, de Herder WW, Valk GD (2015) Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group [DMSG]. J Clin Endocrinol Metab 100:3288–3296CrossRefPubMed
8.
Zurück zum Zitat Beckers A, Betea D, Socin HV, Stevenaert A (2003) The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 253:599–605CrossRefPubMed Beckers A, Betea D, Socin HV, Stevenaert A (2003) The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 253:599–605CrossRefPubMed
9.
Zurück zum Zitat Syro LV, Scheithauer BW, Kovacs K, Toledo RA, Londoño FJ, Ortiz LD, Rotondo F, Horvath E, Uribe H (2012) Pituitary tumors in patients with MEN1 syndrome. Clinics 67(S1):43–48CrossRefPubMedPubMedCentral Syro LV, Scheithauer BW, Kovacs K, Toledo RA, Londoño FJ, Ortiz LD, Rotondo F, Horvath E, Uribe H (2012) Pituitary tumors in patients with MEN1 syndrome. Clinics 67(S1):43–48CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011CrossRefPubMed Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97:2990–3011CrossRefPubMed
11.
Zurück zum Zitat Gillam MP, Molitch ME (2010) Prolactin. In: Melmed S (ed) The Pituitary, 3rd edn. Elsevier Inc., San Diego, pp 119–166 Gillam MP, Molitch ME (2010) Prolactin. In: Melmed S (ed) The Pituitary, 3rd edn. Elsevier Inc., San Diego, pp 119–166
12.
Zurück zum Zitat Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JAH (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524–529CrossRef Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JAH (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524–529CrossRef
13.
Zurück zum Zitat Serri O, Robert F, Pelletier G, Beauregard H, Hardy J (1987) Hyperprolactinemia associated with clinically silent adenomas: endocrinologic and pathologic studies; a report of two cases. Fertil Steril 47:792–796CrossRefPubMed Serri O, Robert F, Pelletier G, Beauregard H, Hardy J (1987) Hyperprolactinemia associated with clinically silent adenomas: endocrinologic and pathologic studies; a report of two cases. Fertil Steril 47:792–796CrossRefPubMed
14.
Zurück zum Zitat Losa M, Mortini P, Giovanelli M (2004) A non-functioning pituitary adenoma initially mimicking a microprolactinoma: the case for long-term follow-up of patients with mild hyperprolactinemia? J Endocrinol Invest 27:367–370 Losa M, Mortini P, Giovanelli M (2004) A non-functioning pituitary adenoma initially mimicking a microprolactinoma: the case for long-term follow-up of patients with mild hyperprolactinemia? J Endocrinol Invest 27:367–370
15.
Zurück zum Zitat Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85:1789–1793PubMed Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR (2000) The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 85:1789–1793PubMed
16.
Zurück zum Zitat Pontiroli AE, Falsetti L (1984) Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics. B.M.J 288:515–518CrossRef Pontiroli AE, Falsetti L (1984) Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics. B.M.J 288:515–518CrossRef
17.
Zurück zum Zitat Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418CrossRefPubMed Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418CrossRefPubMed
18.
Zurück zum Zitat Sluijmer AV, Lappöhn RE (1992) Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58:72–77CrossRefPubMed Sluijmer AV, Lappöhn RE (1992) Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 58:72–77CrossRefPubMed
19.
Zurück zum Zitat Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288CrossRefPubMed
20.
Zurück zum Zitat Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho L, Wass J, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho L, Wass J, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273CrossRef
21.
Zurück zum Zitat Chuang E, Molitch M (2005) Need for periodic pituitary imaging in patients with MEN I syndrome. Presented at the 9th international pituitary congress, San Diego, June, 2005, Abstract #15. Pituitary 7 4 Chuang E, Molitch M (2005) Need for periodic pituitary imaging in patients with MEN I syndrome. Presented at the 9th international pituitary congress, San Diego, June, 2005, Abstract #15. Pituitary 7 4
Metadaten
Titel
Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels
verfasst von
Alina Livshits
Jelena Kravarusic
Ellie Chuang
Mark E. Molitch
Publikationsdatum
06.09.2016
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 6/2016
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-016-0752-z

Weitere Artikel der Ausgabe 6/2016

Pituitary 6/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.